Austin, United States, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Uterine Fibroid Market Size & Growth Analysis: As Per SNS Insider, The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033 and grow at a CAGR of 7.63% over the forecast period 2026-2033. The uterine fibroid market is expanding at a high growth rate due to the increased incidence of uterine fibroids among women of childbearing age in the world. Uterine fibroids, also known as leiomyomas, ...

格隆汇2月14日｜13F报告显示：Maverick Capital Ltd.四季度建仓做多谷歌C、应用材料、波士顿科学、 Visa、以及Camden Property。增持台积电、英伟达、GFL Environment、Carvana。清仓Kenvue、美国银 行、AMD、Danaher、以及Insmed。减持Nubank、迪士尼、Merit Medical、Acadia Health、Sherwin- Williams。重仓英伟达、微软、亚马逊、台积电、谷歌C。 ...

Core Viewpoint - The comparison between Merit Medical (MMSI) and Straumann Holding AG (SAUHY) indicates that MMSI is currently viewed as the better option for investors seeking undervalued stocks due to its stronger earnings estimate revisions and favorable valuation metrics [1][3]. Group 1: Zacks Rank and Earnings Estimates - MMSI has a Zacks Rank of 2 (Buy), while SAUHY has a Zacks Rank of 3 (Hold), suggesting that MMSI's earnings estimate revision activity is more favorable [3]. - The Zacks Rank system emphasizes stocks with strong earnings estimate revision trends, which is a positive indicator for MMSI [2]. Group 2: Valuation Metrics - MMSI has a forward P/E ratio of 20.07, compared to SAUHY's forward P/E of 28.57, indicating that MMSI may be undervalued relative to SAUHY [5]. - The PEG ratio for MMSI is 1.95, while SAUHY's PEG ratio is 2.78, further supporting the notion that MMSI offers better value based on expected EPS growth [5]. - MMSI's P/B ratio stands at 3.15, significantly lower than SAUHY's P/B of 8.14, reinforcing the argument for MMSI being the more attractive investment option [6]. Group 3: Value Grades - Based on various valuation metrics, MMSI holds a Value grade of B, while SAUHY has a Value grade of C, indicating that MMSI is perceived as a better value investment [6].

Core Viewpoint - Merit Medical (MMSI) shows potential for significant upside, with a mean price target of $104.27 indicating a 26.8% increase from its current price of $82.22 [1] Price Targets and Estimates - The mean estimate consists of 11 short-term price targets with a standard deviation of $9.12, suggesting variability among analysts [2] - The lowest estimate is $90.00, indicating a 9.5% increase, while the highest estimate is $122.00, suggesting a potential surge of 48.4% [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts exhibit growing optimism about MMSI's earnings prospects, as indicated by upward revisions in EPS estimates [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.2%, with two estimates moving higher and no negative revisions [12] - MMSI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Considering buying MMSI stock? Here’s what analysts think: Photo via Shutterstock ...

Core Insights - Women We Admire has announced The Top 50 Women Leaders of Delaware for 2026, highlighting the significant role Delaware plays in the U.S. corporate and financial landscape, with over half of publicly traded companies and two-thirds of Fortune 500 firms incorporated there [1][2] Group 1: Economic and Corporate Landscape - Delaware's economy is characterized by a mix of business and financial services, science and technology, manufacturing, and logistics, supported by a skilled workforce and a favorable legal environment with low taxes and streamlined regulations [1] - The state is recognized for its corporate governance standards, making it a preferred location for many companies [1] Group 2: Honorees and Their Contributions - Alonna Berry, Executive Director of the Delaware Center for Justice, has over 15 years of experience in education, public policy, and nonprofit leadership, focusing on organizational development and community-rooted approaches [3] - Lisa Brubaker, Executive Vice President and Chief Human Resources Officer of WSFS Bank, has 27 years of experience in technology and operations, significantly impacting technological platforms and operational efficiency [4] - Shonette Carew, Executive Vice President and Chief Administrative Officer of Blood Cancer United, has over two decades of experience in various fields, overseeing business operations and fostering a culture of collaboration and innovation [5] Group 3: Recognition and Celebration - The announcement serves to celebrate the accomplishments of influential women leaders in Delaware, showcasing their impact on economic activity and community support [2][6]

Core Insights - Merit Medical Systems, Inc. (MMSI) is positioned for growth due to a strong product portfolio and optimistic performance outlook for 2025, despite facing macroeconomic headwinds and forex volatility [2][3] Growth Drivers - WRAPSODY CIE is a significant growth engine for MMSI, supported by favorable reimbursement dynamics and early signs of adoption among physicians [6][8] - The initiation of outpatient and ASC reimbursement under Transitional Pass-Through (TPT) in January 2026 could expand the addressable market [7] - New product launches and acquisitions are expected to enhance the high-margin product mix, supporting organic growth and margin expansion [10][11] Financial Performance - MMSI has a market capitalization of $4.8 billion and projects a 10.3% growth rate over the next five years [3] - The company has delivered an average earnings surprise of 14.1% over the past four quarters [3] - A long-term target includes generating over $400 million in cumulative free cash flow through 2026, driven by gross margin expansion [13][14] Challenges - Reimbursement and policy uncertainty remain key risks, particularly regarding the timing of TPT reimbursement for WRAPSODY [15][16] - Macroeconomic headwinds, especially in China, could affect growth consistency and lead to revenue volatility in the OEM business [17][18] Estimate Trends - The Zacks Consensus Estimate for EPS has increased by 1.5% to $4.05 for 2026, with first-quarter 2026 revenue estimates at $379.6 million, indicating a 6.8% rise year-over-year [19]

Company Overview - Merit Medical has appointed Martha Aronson as the new CEO, succeeding founder Fred Lampropoulos, effective October 3, 2025 [2] - Martha Aronson has extensive experience in the medical technology industry, having previously worked at Medtronic, Hill-Rom, and Ecolab Healthcare [2] Leadership - Martha Aronson expressed excitement about her new role and is joined by Raul Parra, the CFO, who has been with the company for 16 years and served as CFO for the last 7.5 years [1][2] Business Strategy - The presentation will cover a brief company history, an overview of the business, key products, and the go-to-market strategy [3]

Summary of Merit Medical Systems FY Conference Call Company Overview - **Company Name**: Merit Medical Systems (NasdaqGS: MMSI) - **CEO**: Martha Aronson, appointed on October 3, 2025, succeeding founder Fred Lampropoulos [1][2] - **Market Cap**: Over $5 billion with revenues of $1.5 billion as of 2025 [3][4] - **Employee Count**: Over 7,500 employees globally [3] - **Global Footprint**: Vertically integrated manufacturing in Salt Lake City, Tijuana, Galway, and Singapore [3] Financial Performance - **Revenue Growth**: Total revenue increased at a 10% compounded annual growth rate (CAGR) over the last three years [4] - **Revenue Segmentation**: Approximately 40% of revenue from international customers and 60% from U.S. customers [4] - **Product Segmentation**: Revenue reported in two segments: cardiovascular and endoscopy [4] - **Foundational Products**: Comprise about two-thirds of revenue with a 6% CAGR over the last three years [5] - **Therapeutic Products**: Comprise about one-third of revenue with a 19% CAGR over the last three years [5] Strategic Initiatives - **Mergers and Acquisitions**: Over $1 billion invested in M&A since 2016, crucial for growth [3] - **Continued Growth Initiatives (CGI)**: Targeting a 5%-7% CAGR in revenue, 20%-22% non-GAAP operating margin, and over $400 million in cumulative free cash flow from FY23 to FY26 [15][14] - **Recent Performance**: Preliminary revenue for 2025 projected at $1.5 billion, up 11% [15] Product Development and Innovation - **Cardiac Therapies**: One of the fastest-growing segments with mid-teens growth; includes lead extraction technology from Cook Medical [8] - **Endoscopy Portfolio**: Focus on GERD treatment and tumor localization for breast cancer with the Scout system [9][10] - **Renal Therapies**: Includes dialysis products and the WRAPSODY endoprosthesis for dialysis patients [10][11] Market Position and Competitive Strategy - **Customer Focus**: Emphasis on being a customer-focused organization, leveraging both organic and inorganic growth strategies [29] - **Acquisition Strategy**: Active in pursuing small tuck-in acquisitions to fill strategic gaps, with a disciplined financial approach [36][37] - **Global Market Strategy**: Direct sales combined with distributor partnerships in international markets [12] Challenges and Considerations - **Tariffs Impact**: Anticipated impact of $13-$15 million from tariffs in 2026 [23] - **OEM Business**: Experienced softness due to a slowdown in the coatings business in China [21] - **Reimbursement Issues**: WRAPSODY faced challenges with reimbursement approvals, but the company is pivoting its pricing strategy [30] Leadership Transition - **Board Changes**: Fred Lampropoulos resigned as chairman; F. Ann Millner appointed as new chairman [22] - **Leadership Confidence**: The transition is seen as smooth, with confidence in the internal team's readiness to continue the company's momentum [22] Future Outlook - **Focus on Growth**: Continued emphasis on scaling the business globally while reinforcing existing infrastructure [28] - **Long-term Planning**: Strategy development for 2027-2030 to be informed by current growth platforms [18] - **Investment in R&D**: Plans to prioritize R&D efforts based on customer needs and market opportunities [18][46] This summary encapsulates the key points from the conference call, highlighting Merit Medical's financial performance, strategic initiatives, product development, market positioning, challenges, and future outlook.

Revenue Performance - Merit Medical reported preliminary unaudited revenue for Q4 2025 in the range of approximately $389 million to $395 million, representing an increase of approximately 10% to 11% year-over-year[9]. - Preliminary unaudited constant currency revenue for Q4 2025 increased by approximately 8% to 10% year-over-year[9]. - The impact of foreign exchange on preliminary revenue was approximately $(4.4) million for the three-month period ended December 31, 2025[13]. - Merit Medical's preliminary unaudited revenue information should not be regarded as a reliable prediction of actual future results[23]. Financial Guidance and Reporting - The company plans to announce its financial results for the year ended December 31, 2025, and issue fiscal year 2026 guidance on February 24, 2026[7]. - Merit Medical's management emphasizes the importance of non-GAAP financial measures, such as constant currency revenue, for evaluating business trends and performance[10]. Strategic Initiatives - Merit Medical's Continued Growth Initiatives aim to achieve related financial targets for the three-year period ending December 31, 2026[5]. - Merit Medical is focused on integrating the C2 CryoBalloon device and related assets acquired from Pentax of America, Inc. in November 2025[19]. Leadership and Workforce - The company has undergone a leadership transition, with F. Ann Millner appointed as Chair of the Board effective January 5, 2026[1]. - Merit Medical employs approximately 7,500 people worldwide and serves customers globally with a sales force and clinical support team of over 800 individuals[17].